Abstracts tagged "gout"

Abstract Number: 0665 • ACR Convergence 2020
Trends in Immunomodulation/pegloticase Co-therapy from 2015-2019: A Claims Database Study
Brian LaMoreaux¹, John Botson², Megan Francis-Sedlak¹, Karl Svensson¹ and Robert Holt¹, ¹Horizon Therapeutics plc, Lake Forest, IL, ²Orthopedic Physicians Alaska, Anchorage, AK
Background/Purpose: Pegloticase, a recombinant, PEGylated uricase enzyme, is used to treat uncontrolled gout in patients who do not improve on or are intolerant of oral…
Abstract Number: 0686 • ACR Convergence 2020
Renal Evolution During the First Year of Urate-lowering Therapy According to Sonographic Joint Deposition: Data from the Lille-Alicante Inception Cohort
Irene Calabuig¹, Anne Marty-Ané², Laurène Norberciak³, Jean--Francois Budzik⁴, Agustín Martínez-Sanchis⁵, Mariano Andrés¹ and Tristan Pascart³, ¹Hospital General Universitario de Alicante-ISABIAL and Universidad Miguel Hernández de Elche, Alicante, Spain, ²GHICL, Lille, France, ³GHICL, Lomme, France, ⁴University of Lille, Lille, France, ⁵Hospital General Universitario de Alicante-ISABIAL, Alicante, Spain
Background/Purpose: Gout is associated with chronic kidney disease, but how the kidney function evolves when gout is treated with urate lowering therapy (ULT) is still…
Abstract Number: 1607 • ACR Convergence 2020
Effectiveness of Dietary Counseling on Gout Management and Risk Factors for Metabolic Syndrome in Gout Patients
Juliana Chang¹, Jonathan Tsui² and Maida Wong³, ¹Division of Rheumatology, Department of Medicine, University of California Irvine, Irvine, CA, ²Geisinger Medical Center, Danville, PA, ³Division of Rheumatology, Department of Medicine, VA Long Beach Healthcare System, Long Beach, CA
Background/Purpose: Gout is the most prevalent inflammatory arthritis globally. Despite treatment advances, the prevalence of gout has continued to increase over the last several decades.…
Abstract Number: 0649 • ACR Convergence 2020
A Multicenter, Open-Label, Efficacy and Safety Study of Pegloticase in Patients with Uncontrolled Gout Who Have Undergone Kidney Transplantation: Early Data Report
Abdul Abdellatif¹, Lin Zhao², Paul Peloso³, Katya Cherny², Brad Marder², John Scandling⁴ and Kenneth Saag⁵, ¹Baylor College of Medicine, Division of Nephrology, Houston, TX, ²Horizon Therapeutics plc, Lake Forest, IL, ³Horizon Therapeutics plc, Gurnee, IL, ⁴Stanford Medicine, Department of Nephrology, Stanford, CA, ⁵University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, Birmingham, AL
Background/Purpose: Gout’s high prevalence in kidney transplant (KT) recipients has been associated with heavy residual urate burden, decreased urate excretion related to reduced renal function,…
Abstract Number: 0667 • ACR Convergence 2020
Gout Management Beyond Prescription Writing: The Role of the Pharmacist
Emma Dorris¹, Paul Ryan², Mariosa Kieran³, Nicola Dalbeth⁴ and Geraldine McCarthy⁵, ¹School of Medicine, Dublin, Dublin, Ireland, ²Mayfield Family Practice, Cork, Cork, Ireland, ³Pharmacy Department, Dublin, Dublin, Ireland, ⁴University of Auckland, Auckland, New Zealand, ⁵University College Dublin, Dublin, Dublin, Ireland
Background/Purpose: Urate lowering therapy (ULT) is recommended for long-term gout management. However, gout flares are common at the time of starting ULT, and these flares…
Abstract Number: 0688 • ACR Convergence 2020
The Discontinuation of Allopurinol in the Inpatient Setting and the Risk of Gout Flare: A Community-Hospital Experience
Artem Minalyan¹, Waqas Ullah², Shristi Khanal³, Bikash Basyal⁴ and Qian Zhang³, ¹Department of Medicine/Abington Hospital - Jefferson Health, Jenkintown, PA, ²Department of Medicine/Abington Hospital - Jefferson Health, Horsham, ³Department of Medicine/Abington Hospital - Jefferson Health, Jenkintown, ⁴Department of Medicine/Abington Hospital - Jefferson Health, Abington
Background/Purpose: The discontinuation of urate-lowering therapy (ULT) in the outpatient setting increases the risk of gout flare. It was reported that in hospitalized patients with…
Abstract Number: 1628 • ACR Convergence 2020
Management of Gout After Pegloticase; Observations of US Clinical Practice from Trio Health and the American Rheumatology Network (ARN)
Nehad Soloman¹, Mona Amin², Simon Helfgott³, Alexander Hu⁴, Kent Kwas Huston⁵, Jordan Leonard⁶, Kelsey Milligan⁷, Scott Milligan⁷, Jasvinder Singh⁸, John Tesser⁹ and Colin Edgerton¹⁰, ¹Arizona Arthritis & Rheumatology Associates, P.C., Peoria, AZ, ²Arizona Arthritis & Rheumatology Associates, P.C., Scottsdale, AZ, ³BWH- HMS, Boston, MA, ⁴Arizona Arthritis & Rheumatology Associates, P.C., New Orleans, LA, ⁵Kansas City Physician Partners, Kansas City, MO, ⁶Arizona Arthritis & Rheumatology Associates, P.C., Phoenix, AZ, ⁷Trio Health, Louisville, CO, ⁸University of Alabama at Birmingham, Birmingham, AL, ⁹Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, ¹⁰Articularis Healthcare, Summerville, SC
Background/Purpose: Pegloticase is approved for severe gout in patients that are intolerant to, or whose disease is ineffectively controlled by, other uric acid lowering therapies…
Abstract Number: 0650 • ACR Convergence 2020
Risk of Vertebral Fractures at Lateral Chest Radiographies in Patients with Gout
Marco Ferrández-Jiménez¹, Irene Calabuig², Maria Luisa Peral², Miguel Gómez-Garberí¹ and Mariano Andrés², ¹Universidad Miguel Hernández de Elche, Alicante, Spain, ²Hospital General Universitario de Alicante-ISABIAL and Universidad Miguel Hernández de Elche, Alicante, Spain
Background/Purpose: Osteoporosis causes significant morbidity and mortality through the development of fragility fractures, including vertebral fractures (VF). Patients with gout may show an increased risk…
Abstract Number: 0669 • ACR Convergence 2020
Calcium Pyrophosphate Crystal Deposition in Gouty Tophi
Hang-Korng Ea¹, Alan Gauffenic², Quand Nguyen³, Nhu Pham³, Oceane Olivier², Vincent Frochot⁴, Dominique Bazin⁵, Nghia Le³, Caroline Marty², Agnès Ostertag², Martine Cohen-Solal¹, Jean-Denis Laredo⁶, Pascal Richette⁷ and Thomas Bardin⁸, ¹Université de Paris, INSERM UMR 1132, BIOSCAR, AP-HP, DMU Locomoteur, Paris, France, ²Université de Paris, INSERM UMR 1132, BIOSCAR, Paris, France, ³Vien Gut Medical Center and French-Vietnamese research center on gout and chronic diseases, Ho Chi Ming, Vietnam, ⁴Hôpital Tenon, Service des explorations fonctionnelles multidisciplinaires, Sorbonne université, UMR_S1155, Paris, France, ⁵Institut de Chimie Physique, Université Paris-Saclay et CNRS - UMR8000, Orsay, France, ⁶AP-HP Université de Paris, Paris, ⁷Department of Rheumatology, Lariboisière Hospital, AP-HP Université de Paris, INSERM U1132, Paris, ⁸Université de Paris, INSERM U1132 and Hôpital Lariboisièe, Paris, France, Paris, France
Background/Purpose: The coexistence of calcium pyrophosphate (CPP) and monosodium urate crystals is rarely reported in gouty tophi. We investigated CPP crystal deposits in a series…
Abstract Number: 0689 • ACR Convergence 2020
The Changing Epidemiology of Inpatient Gout and Associated Mortality: A 17-year National Study
Jasvinder Singh¹ and John Cleveland¹, ¹University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Knowledge gaps exist regarding time-trends for the main causes (Cardiac/renal disease vs. infections) hospitalizations in gout. Therefore, we examined whether specific causes (cardiovascular, renal,…
Abstract Number: 1629 • ACR Convergence 2020
Management of Gout with Pegloticase; Real-World Utilization and Outcomes from Trio Health and the American Rheumatology Network (ARN)
Nehad Soloman¹, Mona Amin², Kimmi Cox³, Simon Helfgott⁴, Alexander Hu⁵, Kent Kwas Huston⁶, Jordan Leonard⁷, Scott Milligan³, Jasvinder Singh⁸, John Tesser⁹ and Colin Edgerton¹⁰, ¹Arizona Arthritis & Rheumatology Associates, P.C., Peoria, AZ, ²Arizona Arthritis & Rheumatology Associates, P.C., Scottsdale, AZ, ³Trio Health, Louisville, CO, ⁴BWH- HMS, Boston, MA, ⁵Arizona Arthritis & Rheumatology Associates, P.C., New Orleans, LA, ⁶Kansas City Physician Partners, Kansas City, MO, ⁷Arizona Arthritis & Rheumatology Associates, P.C., Phoenix, AZ, ⁸University of Alabama at Birmingham, Birmingham, AL, ⁹Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, ¹⁰Articularis Healthcare, Summerville, SC
Background/Purpose: Infusion reactions and other adverse events associated with pegloticase may lead to discontinuation of treatment in patient populations that have already failed or are…
Abstract Number: 0651 • ACR Convergence 2020
Readmission Risk and Quality of Care in Patients Presenting to the Emergency Department with Gout Flares
Luigi Brunetti¹, Janaki Vekaria¹, Peter Lipsky² and Naomi Schlesinger³, ¹Rutgers Ernest Mario School of Pharmacy, piscataway, NJ, ²AMPEL BioSolutions LLC., Charlottesville, VA, ³Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ
Background/Purpose: Gout is the most common inflammatory arthritis and its economic burden is substantial, with estimates for the overall cost exceeding $20 billion (US) annually.…
Abstract Number: 0671 • ACR Convergence 2020
Structured Cardiovascular Assessment in Gout Incorporating Carotid Ultrasound: Analysis of Subsequent Events in the Follow-Up
Mar Monzó¹, Neus Quilis², Laura Ranieri², Alejandro San-Martín³ and Mariano Andrés⁴, ¹Universidad Miguel Hernández, Alicante, Spain, ²Hospital Universitario del Vinalopó, Alicante, Spain, ³Clínica HLA Vistahermosa, Alicante, Spain, ⁴Hospital General Universitario de Alicante-ISABIAL and Universidad Miguel Hernández de Elche, Alicante, Spain
Background/Purpose: Gout is an independent cardiovascular (CV) risk factor. This excess of morbidity and mortality requires optimal management, especially in high-risk individuals. Therefore, the inclusion…
Abstract Number: 0690 • ACR Convergence 2020
AR882, a Potent and Selective Uricosuric Agent, Significantly Reduced Serum Urate in Patients with Gout in a Phase 2a Study
Li-Tain Yeh¹, Elizabeth Polvent¹, Zancong Shen², Vijay Hingorani¹, Andrea Clouser-Roche¹, Chris Mikelatis¹, Shunqi Yan¹ and Rongzi Yan¹, ¹Arthrosi Therapeutics Inc, Laguna Hills, CA, ²Arthrosi therapeutics, Laguna Hills, CA
Background/Purpose: AR882 is a potent and selective uric acid transporter 1 (URAT1) inhibitor under development for the treatment of hyperuricemia or gout. Phase 1 single…
Abstract Number: 332 • 2019 ACR/ARP Annual Meeting
Incident Gout After Renal Transplantation in Gout-naïve Patients: Large Database Analysis
Brian LaMoreaux¹, Megan Francis-Sedlak ¹ and Robert Holt ¹, ¹Horizon Therapeutics plc, Lake Forest, IL
Background/Purpose: Patients undergoing kidney transplantation are at increased risk for developing hyperuricemia and gout compared to the general population (generally attributed to the frequent use…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].